US Bancorp DE Increases Stock Position in Grifols, S.A. (NASDAQ:GRFS)

US Bancorp DE grew its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 12.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,663 shares of the biotechnology company’s stock after purchasing an additional 2,256 shares during the period. US Bancorp DE’s holdings in Grifols were worth $183,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Brandes Investment Partners LP lifted its holdings in Grifols by 8.7% in the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock valued at $117,242,000 after acquiring an additional 1,481,924 shares during the period. Armistice Capital LLC increased its holdings in shares of Grifols by 18.7% in the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares in the last quarter. Capital World Investors lifted its stake in shares of Grifols by 4.9% in the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock valued at $138,605,000 after purchasing an additional 961,700 shares during the period. Highland Peak Capital LLC purchased a new stake in Grifols during the second quarter worth about $5,991,000. Finally, Black Creek Investment Management Inc. grew its position in Grifols by 7.7% during the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after buying an additional 881,155 shares during the period.

Grifols Stock Performance

Grifols stock opened at $9.55 on Friday. Grifols, S.A. has a fifty-two week low of $5.30 and a fifty-two week high of $12.15. The stock’s fifty day moving average is $8.85 and its two-hundred day moving average is $7.97. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.